Thrombolytic therapy in acute myocardial infarction

Drugs of Today

Volumn 34, Issue 8, 1998, Pages 727-736

  Dangas, George ^a,b   Fier, Carl ^a   Ambrose, John A ^a  

^a MOUNT SINAI HOSPITAL   (United States)

^b Washington Cardiology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; HEPARIN; LAMIFIBAN; RAPID 11; SARUPLASE; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CLINICAL FEATURE; DRUG FORMULATION; DRUG POTENCY; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT PLANNING;

EID: 0031718022     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.8.485271     Document Type: Review

References (47)

1. Fuster, V., Badimon, L., Badimon, J.J., Chesebro, J. The pathophysiology of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992, 326: 242-50, 310-8.
2. Ambrose, J.A., Winters, S.L., Arora, R.R. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986, 7: 472-8.
3. Braunwald, E. The open-artery theory is alive and well - Again. New Engl J Med 1993, 329: 1650-2.
4. Ambrose, J.A., Weinrauch, M. Thrombosis in ischemic heart disease. Arch Intern Med 1996, 156 (13): 1382-94.
5. Braunwald, E., Jones, R.H., Mark, D.B. et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994, 90: 613-22.
6. Schrier, S.L., Leung, L.L.K. Disorders of hemostasis and coagulation. In: Scientific American Medicine: A Comprehensive Knowledge Base of Internal Medicine. Dale, D.C. (Ed.). Scientific American Inc.: New York 1997, 1-53.
7. Physicians' Desk Reference, 51st Ed. Medical Economics Co.: Oradell, NJ 1997.
8. Fears, R. The effect of heparin and fibrin on the enzymatic efficiencies of thrombolytics in vitro. Drugs 1987, 33 (Suppl. 3): 69-74.
9. Eisenberg, P.R., Sherman, L.A., Tiefenbrunn, A.J. et al. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Haemost 1987, 57: 35-40.
10. ISIS (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2: 349-60.
11. Gruppo Italiano per lo Studia della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986, 1: 397-402.
12. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988, 1: 545-9.
13. Fibrinolytic Therapy Trialisis (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994, 343: 311-22.
14. Simoons, M.L., Maggioni, A.P., Knatterud, G. et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993, 342: 1523-8.
15. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993, 329: 673-82.
16. Dalen, J.E., Gore, J.M., Braunwald, E. et al. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Am J Cardiol 1988, 62: 179-85.
17. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I findings. New Engl J Med 1985, 312: 932-6.
18. Karagounis, L., Sorensen, S.G., Menlove, R.L. et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 Study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 1992, 19: 1-10.
19. Anderson, J.L., Karagounis, L.A., Becker, L.C. et al. TIAIM perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993, 87: 1829-39.
20. The GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. New Engl J Med 1993, 329: 1615-22.
21. Cannon, C.P., McCabe, C.H., Diver, D.J. et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994, 24: 1602-10.
22. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990, 336: 65-71.
23. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990, 336: 71-5.
24. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992, 339: 753-70.
25. Grines, C.L., Nissen, S.E., Booth, D.C. et al. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 1991, 84: 540-9.
26. Neuhaus, K-L., von Essen, R., Tebbe, U. et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC Patency Study (TAPS). J Am Coll Cardiol 1992, 19: 885-91.
27. Kleiman, N.S., White, H.D., Ohman, E.M. et al. Mortality within 24 hours of thrombolysis in myocardial infarction. The importance of early reperfusion. Circulation 1994, 90: 2658-65.
28. Califf, R.M., White, H.D., Van de Werf, F. et al. One year results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-1) trial. Circulation 1996, 94: 1233-8.
29. Collen, D., Lijnen, H.R. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 1994, 84: 680-6.
30. Vanderschueren, S., Collen, D., Van de Werf, F. Coronary reperfusion in patients with an acute myocardial infarction following intravenous administration of recombinant Staphylokinase. J Am Coll Cardiol 1994, Special Issue): Abst 315A.
31. Keyt, B.A., Paoni, N.F., Refino, C.J. et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994, 91: 3670-4.
32. Smalling, R.W., Bode, C., Kalbfleisch, J. et al. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995, 91: 2725-32.
33. Bode, C., Smalling, R.W., Berg, G. et al. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (r-PA) and front loaded, accelerated alteplase (rt-PA) in patients with acute myocardial infarction. Circulation 1996, 94: 891-8.
34. Bode, C., Nordt, T.K., Runge, M. Thrombolytic therapy in acute myocardial infarction -Selected recent developments. Ann Hematol 1994, 69: 535-40.
35. The Global Use of Strategies to Open Occluded Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction2E New Engl J Med 1997, 377: 1118-23.
36. Benedict, C.R., Refino, C., Keyt, B.A. et al. A new variant of tissue plasminogen activator (tPA) with enhanced efficacy and lower incidence of bleeding when compared with recombinant human t-PA. Circulation 1995, 92: 3032-40.
37. Coller, B.S., Scudder, L.R. Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985, 66: 1456-9.
38. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high ristreptokinase angioplasty. New Eng) J Med 1994, 330: 956-61.
39. Kleiman, N., Ohman, E.M., Califf, P.M. et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993, 22: 381-9.
40. ReoPro-MI pilot trial. Oral presentation at the 10th Transcatheter Cardiovascular Therapeutics Conference, Washington, DC 1997.
41. Ohman, E.M., Kleiman, N.S., Gagioch, G. et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997, 95: 846-54.
42. The EPILOG Investigors. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. New Engl J Med 1997, 366: 1689-96.
43. Topol, E.J., George, B.S., Kereiakis, D.J. et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989, 79: 281-6.
44. Hsia, J., Hamilton, W.P., Kleiman, N. et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. New Engl J Med 1990, 323: 1433-7.
45. de Bono, D.P., Simoons, M.I., Tijssen, T. et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteptase thrombolysis: Results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992, 67: 122-8.
46. Thompson, P.L., Aylward, P.E., Federman, J. et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991, 83: 1534-42.
47. Ridker, P.M., Hebert, P.R., Fuster, V. et al. Are both aspirin and heparin justified as adjunctions to thrombolytic therapy for acute myocardial infarction? Lancet 1993, 341: 1574-7.